Target Audience

This program is designed for hematologists/oncologists, dermatologists, researchers, physician assistants, nurses and students.

Learning Objectives

At the conclusion of this activity, attendees should be better able to:

  • Describe new diagnostic and surveillance techniques, and follow-up of patients with early melanoma using the latest technologies.
  • State the role of complete node dissections for microscopic nodal disease based on current evidence that assesses the clinical utility of sentinel node mapping in the management of malignant melanoma.
  • Assess the current state of adjuvant therapy and options that may be available in the future.
  • Compare the advantages and limitations of intralesional, locoregional and systemic interventions for treatment of advanced cutaneous malignancies.
  • Assess unique clinical situations such as brain metastases, Merkel cell carcinoma, adnexal carcinoma and uveal melanoma and determine appropriate treatment approaches.
  • Examine recent evidence about basal cell carcinomas and hedgehog inhibition, and the management of cutaneous t-cell lymphomas and aggressive squamous cell carcinomas.
  • Review potential benefits and adverse effects of emerging therapeutic agents for the treatment of primary cutaneous malignancies.
  • Obtain an understanding of the role of currently available and potential future applications of immunotherapy and targeted therapy for advanced melanoma.
  • Analyze outcomes from investigative clinical trials that involve the use of adjuvant therapy and novel biologics for the treatment of high risk melanoma.
  • Determine how to best utilize the various biomarkers and correlate with outcome to optimize care for patients with melanoma.
  • Evaluate the potential positive impact that interdisciplinary approaches to melanoma treatment may have on patient outcomes.
  • Analyze potential algorithms for the treatment of advanced melanomas, using newly approved agents, to assist in therapeutic decision making.
  • Determine the best clinical follow up algorithms for high-risk melanoma.
  • Examine the implications and effect of the costs associated with melanoma therapy and their potential impact on patient health and the health care system.
This continuing medical education activity is provided by

ACCREDITATION: Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION: This live activity is approved for AMA PRA Category 1 Credit(s)™.

NURSES: For the purpose of recertifying with the ANCC, AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME can be used.

FACULTY/PLANNER DISCLOSURE POLICY: In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

NOTICE: Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.